PBU The Pension Fund of Early Childhood & Youth Educators Purchases 13,968 Shares of Bristol Myers Squibb Company $BMY

PBU The Pension Fund of Early Childhood & Youth Educators increased its position in Bristol Myers Squibb Company (NYSE:BMY) by 6.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 233,660 shares of the biopharmaceutical company’s stock after purchasing an additional 13,968 shares during the period. PBU The Pension Fund of Early Childhood & Youth Educators’ holdings in Bristol Myers Squibb were worth $14,580,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. BlackRock Inc. boosted its holdings in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. State Street Corp raised its holdings in shares of Bristol Myers Squibb by 7.3% in the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock valued at $6,093,755,000 after purchasing an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA purchased a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Bristol Myers Squibb by 0.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock valued at $1,315,984,000 after purchasing an additional 119,690 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Bristol Myers Squibb by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company’s stock valued at $1,137,847,000 after purchasing an additional 520,330 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $62.42 on Friday. The company has a market capitalization of $127.58 billion, a P/E ratio of 13.84, a P/E/G ratio of 0.32 and a beta of 0.20. The business has a fifty day simple moving average of $61.99 and a two-hundred day simple moving average of $60.27. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.59 and a quick ratio of 1.44. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same quarter in the prior year, the company earned $1.63 EPS. The firm’s quarterly revenue was up 6.9% compared to the same quarter last year. On average, analysts expect that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.

Insider Activity at Bristol Myers Squibb

In related news, Director Julia Haller sold 3,800 shares of the company’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This represents a 11.15% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. The trade was a 2.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on BMY. Piper Sandler cut their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating on the stock in a research report on Monday, October 26th. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, July 27th. JPMorgan Chase & Co. boosted their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Truist Financial set a $70.00 price target on shares of Bristol Myers Squibb in a research report on Friday, October 30th. Finally, Raymond James Financial began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “strong-buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $65.46.

Latest Bristol Myers Squibb News

Here’s some of the latest news about BMY:

• Positive Sentiment: Some analysts and commentators consider BMY attractively valued, citing roughly 10 times forward earnings and a view that shares remain below fair value despite a strong multi-year run. That could support investor interest if the company delivers on its cash-flow and pipeline prospects. Our Bristol Myers Squibb Stock Pick Is Up 35%. It’s Still a Good Bet in Healthcare. Bristol Myers Squibb Stock Looks Below Fair Value Following A 41% Run
• Neutral Sentiment: Bristol Myers plans to bring its scientific and clinical teams together in a unified R&D organization, aiming to accelerate development and make better use of new technologies. Research chief Robert Plenge is leaving as part of the change. The strategy could improve productivity, but the leadership transition and results of the restructuring remain uncertain. Bristol Myers to merge scientific, clinical teams under new R&D structure Bristol Myers research chief to depart in evolution of company’s structure
• Negative Sentiment: Drug-price negotiations are a potential longer-term headwind for BMY, with the article describing the company as facing a bigger test in the years ahead. The risk is not presented as an immediate revenue hit, but could weigh on future pricing and growth expectations. Drug pricing risks for pharmaceutical companies

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.